CONTI vs INDOUS: Stock Comparison
INDO US BIOTECH is the larger company by market capitalisation. CONTI shows faster revenue growth and lower leverage, while INDO US BIOTECH shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CONTI leads 5; INDOUS leads 5 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CONTI | INDOUS |
|---|---|---|
| Sector | — | Fast Moving Consumer Goods |
| Industry | — | Other Agricultural Products |
Price
| Metric | CONTI | INDOUS |
|---|---|---|
| Live Price | — | ₹78.99 |
| Day Change | — | 0.62% |
| Volume | — | 4,002 |
| 52-Week High | — | ₹159 |
| 52-Week Low | — | ₹70 |
| Distance from 52W High | — | -50.32% |
Valuation
| Metric | CONTI | INDOUS |
|---|---|---|
| Market Cap | ₹14 Cr | ₹155 Cr |
| P/E Ratio | — | 0x |
| P/B Ratio | — | 0x |
| EPS | ₹0.72 | ₹5.7 |
| Book Value | ₹23 | ₹45.99 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | CONTI | INDOUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -22% |
| EPS Growth (TTM YoY) | 0% | -47.3% |
| Qtr Sales Growth | 199.1% | -70.13% |
| Qtr Profit Growth | 425.07% | -76.85% |
Profitability & Leverage
| Metric | CONTI | INDOUS |
|---|---|---|
| ROE | 3.13% | 14.18% |
| ROCE | 4.14% | 10.86% |
| Net Margin | 0% | 11.88% |
| Operating Margin | 2.75% | 14.64% |
| Debt to Equity | 0.09x | 0.4x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CONTI | INDOUS |
|---|---|---|
| Promoter Holding | 60.75% | 68.29% |
| FII Holding | 12.19% | 0.01%▼ 0.17 pp |
| DII Holding | 0% | — |
| Public Holding | 27.06% | 31.7%▲ 0.17 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CONTI and INDO US BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.